Polypide

PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board

Retrieved on: 
Tuesday, January 4, 2022
Principal, Private Securities Litigation Reform Act, Disease, Department, Recurrence, Fellowship of the Royal Colleges of Surgeons, Brain, Polypide, PLEX, Securities and Exchange Commission (Philippines), Metastasis, Mortality, Cancer, Survival, Glioblastoma, GLOBE, National Cancer Institute, Company, Neuro, Nature, Docetaxel, National, Research Excellence Framework, University of California, San Francisco, University, Therapy, Patient, Security (finance), UCSF, SPORE, SSIS, American Board of Commissioners for Foreign Missions, Congress of Neurological Surgeons, Technology, American College, Berthold, Neurology, GBM, Forward-looking statement, Medical imaging, Pharmaceutical industry, Oncology

PETAH TIKVA, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Mitchel S. Berger, M.D., to its Oncology Advisory Board.

Key Points: 
  • He serves as the Director of the UCSF Brain Tumor Research Center , a leader in translational research, and is the Principal Investigator of its Specialized Program of Research Excellence (SPORE) in neuro-oncology, funded by the National Cancer Institute.
  • We have made considerable progress in understanding the disease, and PolyPids OncoPLEX has the potential to significantly advance how we treat GBM.
  • I look forward to working closely with PolyPid to further develop OncoPLEX so we can improve patient outcomes.
  • The Company expects to initiate a Phase 1/2 clinical trial of OncoPLEX for brain tumors by the end of 2022.

PolyPid Announces Planned CEO Transition

Retrieved on: 
Monday, January 3, 2022
Growth, Private Securities Litigation Reform Act, Tel Aviv University, Brain, Industry, U.S. Securities and Exchange Commission, Economics, Polypide, PLEX, Board, MBA, Trial of the century, Clinical trial, GLOBE, Compugen, Company, Leadership, NASDAQ, Nature, Â, CEO, Achievement, Therapy, Board of directors, Nasdaq, TASE, Strategic planning, Security (finance), SSIS, History, Technology, Director, Forward-looking statement, Management

Since joining PolyPid seven years ago, she has been instrumental in guiding our financial, strategic and operational objectives.

Key Points: 
  • Since joining PolyPid seven years ago, she has been instrumental in guiding our financial, strategic and operational objectives.
  • Under his leadership, PolyPid is in the strongest operational and financial position in its history, and we thank Amir for his significant contributions as CEO over the past 11 years.
  • It has been an honor to have served as CEO of PolyPid throughout the development phase of our company, stated Mr. Weisberg.
  • Separately, PolyPid announced that Shaul Mukhtar, Ph.D., Chief Operating Officer of PolyPid, will be retiring from the Company, effective March 2022, following two and a half years with PolyPid.

PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery

Retrieved on: 
Thursday, November 18, 2021
SHIELD, Private Securities Litigation Reform Act, Patient, Security (finance), Regulation of tobacco by the U.S. Food and Drug Administration, Safety, Technology, Breakthrough therapy, Surgery, Forward-looking statement, Company, Polypide, U.S. Securities and Exchange Commission, Food, Therapy, PLEX, Disease, Nature, Colorectal surgery, SSIS, QIDP, GLOBE, 500th SS Parachute Battalion, Hospital, FDA, Infection, Pharmaceutical industry

SHIELD I is a pivotal study evaluating D-PLEX100 for the prevention of surgical site infections (SSIs) in abdominal surgery.

Key Points: 
  • SHIELD I is a pivotal study evaluating D-PLEX100 for the prevention of surgical site infections (SSIs) in abdominal surgery.
  • The trial will continue with patient enrollment, toward approximately 900 patients, in about 60 centers across the United States, Europe and Israel.
  • A blinded review of the overall event rates will commence once the 500th patient completes the 30-day follow-up and is evaluated for the primary endpoint.
  • PolyPids lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).

PolyPid Appoints New Oncology Advisory Board Member

Retrieved on: 
Tuesday, November 16, 2021
Traffic barrier, Cancer, Private Securities Litigation Reform Act, Neurosurgery, MD, Drug discovery, University, Security (finance), Technology, Food, GBM, Brain, Research, MD Anderson Cancer Center, Forward-looking statement, Food and Drug Administration, Polypide, Palestinian National Interest Committee, Docetaxel, Company, U.S. Securities and Exchange Commission, GLOBE, Glioblastoma, Therapy, Nature, Monroe Dunaway Anderson, Death, SSIS, Survival, Patient, PLEX, Pharmaceutical industry

PETAH TIKVA, Israel, Nov. 16, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (PolyPid or the Company), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Frederick Lang, M.D., to its Oncology Advisory Board.

Key Points: 
  • PETAH TIKVA, Israel, Nov. 16, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (PolyPid or the Company), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Frederick Lang, M.D., to its Oncology Advisory Board.
  • In September 2021, PolyPid announced positive preclinical data for its intra-tumoral OncoPLEX in animal models of Glioblastoma Multiform (GBM).
  • I am elated that Dr. Lang has agreed to join PolyPids Oncology Advisory Board, said Amir Weisberg, Chief Executive Officer of PolyPid.
  • Dr. Lang receives compensation as a member of the Oncology Advisory Board, and this financial relationship has been disclosed to MD Andersons Conflict of Interest Committee in accordance with institutional policy.

PolyPid Ltd. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 10, 2021
SHIELD, NDA, Colorectal surgery, Investigational New Drug, Agency, Commercial, Acceleration, Food, GBM, Insurance, Brain, Financial result, Regulation of tobacco by the U.S. Food and Drug Administration, Infection, Polypide, Â, Conference, Company, Research, GLOBE, D&O, Therapy, SSIS, Survival, Marketing, Patient, FDA, Pharmaceutical industry, Medical device, Medicine, Cryptocurrency, Ridesharing company

PETACH TIKVA, Israel, Nov. 10, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focusing on developing targeted, locally administered, and prolonged-release therapeutics to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2021.

Key Points: 
  • FDA agreement that a single pivotal Phase 3 study is sufficient for potential approval will extend PolyPids cash runway to year end 2022.
  • Last-patient-in from SHIELD I is expected to enroll during the second quarter of 2022 with top line results 2 months thereafter.
  • Our cash runway now extends to year-end 2022, a significant improvement over our prior target of the second quarter of 2022.
  • PolyPid expects that its cash on hand will be sufficient to fund operations until the end of 2022.

PolyPid to Present at Upcoming Cantor Fitzgerald Global Healthcare Conference

Retrieved on: 
Monday, September 20, 2021
SHIELD, EDT, Nature, Security (finance), Therapy, SSIS, Conference, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, FDA, PLEX, Polypide, Company, Technology, CFO, Forward-looking statement, GLOBE, Pharmaceutical industry, Risk management

PETAH TIKVA,Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29 at 02:00 pm EDT.

Key Points: 
  • PETAH TIKVA,Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference on September 29 at 02:00 pm EDT.
  • In her presentation, Dikla Czaczkes Akselbrad, Polypids EVP and CFO will provide corporate highlights and discuss recent developments.
  • PolyPid Ltd. (Nasdaq: PYPD ) is a phase 3 biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act and other securities laws.

PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer

Retrieved on: 
Monday, September 13, 2021
Survival, Docetaxel, Therapy, Recurrence, GBM, GLOBE, Polypide, Glioblastoma, PLEX, Pharmaceutical industry, Medical imaging

The OncoPLEX intra-tumoral cancer therapy program was evaluated in brain tumors for tumor growth and survival in two Glioblastoma Multiform (GBM) animal models.

Key Points: 
  • The OncoPLEX intra-tumoral cancer therapy program was evaluated in brain tumors for tumor growth and survival in two Glioblastoma Multiform (GBM) animal models.
  • Local application of OncoPLEX in a rat brain model evidenced good safety profile at the different doses studied.
  • The growing set of data from our OncoPLEX preclinical studies continue to look promising, said Dr. Noam Emanuel, PolyPids co-founder and Chief Scientific Officer.
  • The OncoPLEX intra-tumoral cancer therapy program has been evaluated successfully in various animal tumor models, including colon carcinoma and glioblastoma.

PolyPid to Present at First World Association Against Infection in Orthopaedics and Trauma Congress

Retrieved on: 
Tuesday, August 17, 2021
SHIELD, Company, Private Securities Litigation Reform Act, Congress, Joint, PLEX, Therapy, U.S. Securities and Exchange Commission, Nature, GLOBE, Forward-looking statement, Entrepreneurship, SSIS, Septic, Infection, Polypide, Association, FDA, Technology, Security (finance), Dentistry, Pharmaceutical industry

The event will be attended by 1,700 members coming together virtually from 101 countries.

Key Points: 
  • The event will be attended by 1,700 members coming together virtually from 101 countries.
  • PolyPid Ltd. (Nasdaq: PYPD ) is a late-stage biopharmaceutical company focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes.
  • PolyPids lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act and other securities laws.

PolyPid Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 11, 2021
SHIELD, Hospital, Regulation of tobacco by the U.S. Food and Drug Administration, Brain, Safety, Company, Patient, Hospital-acquired infection, Food, PLEX, Recurrence, Conference, Particle-size distribution, Program, Cancer, Infection, Colorectal surgery, Financial result, SSIS, D&O, Polypide, Surgery, Insurance, NDA, Docetaxel, FDA, GLOBE, Marketing, Research, Communication, Medical imaging, Pharmaceutical industry, Animal, Lithium, Cryptocurrency

PETACH TIKVA, Israel, Aug. 11, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today provided a corporate update and reported financial results for the three and six months ended June 30, 2021.

Key Points: 
  • PETACH TIKVA,Israel, Aug. 11, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today provided a corporate update and reported financial results for the three and six months ended June 30, 2021.
  • Enrollment is also advancing as anticipated in SHIELD II, the second of two Phase 3 clinical trials for D-PLEX100 in abdominal surgery (soft tissue).
  • General and administrative expenses for the second quarter of 2021 were $2.4 million, compared to $2.6 million in the prior year period.
  • PolyPid continues to expect that its cash on hand will be sufficient to fund operations into the second half of 2022.

PolyPid to Present at the Investor Summit Virtual Conference on August 18, 2021

Retrieved on: 
Monday, August 9, 2021
SHIELD, Technology, Private Securities Litigation Reform Act, GLOBE, FDA, SSIS, Polypide, Forward-looking statement, Conference, PLEX, Nature, Company, Pharmaceutical industry

Management will be available for one-on-one meetings to be held throughout the conference.

Key Points: 
  • Management will be available for one-on-one meetings to be held throughout the conference.
  • PolyPid Ltd. (Nasdaq: PYPD ) is a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics.
  • PolyPids lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act and other securities laws.